Recursion Pharmaceuticals Inc (RXRX) concluded trading on Wednesday at a closing price of $7.01, with 4.51 million shares of worth about $31.65 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -6.16% during that period and on October 16, 2024 the price saw a gain of about 5.10%. Currently the company’s common shares owned by public are about 291.36M shares, out of which, 226.81M shares are available for trading.
Stock saw a price change of 13.98% in past 5 days and over the past one month there was a price change of 3.70%. Year-to-date (YTD), RXRX shares are showing a performance of -28.90% which increased to 7.02% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $4.97 but also hit the highest price of $15.74 during that period. The average intraday trading volume for Recursion Pharmaceuticals Inc shares is 4.90 million. The stock is currently trading 6.78% above its 20-day simple moving average (SMA20), while that difference is up 4.92% for SMA50 and it goes to -20.52% lower than SMA200.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Recursion Pharmaceuticals Inc (NASDAQ: RXRX) currently have 291.36M outstanding shares and institutions hold larger chunk of about 74.81% of that.
The stock has a current market capitalization of $2.04B and its 3Y-monthly beta is at 0.80. It has posted earnings per share of -$1.62 in the same period. It has Quick Ratio of 6.07 while making debt-to-equity ratio of 0.15. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for RXRX, volatility over the week remained 5.72% while standing at 5.34% over the month.
Stock’s fiscal year EPS is expected to rise by 1.11% while it is estimated to decrease by -9.87% in next year. EPS is likely to grow at an annualized rate of 12.00% for next 5-years, compared to annual growth of -43.41% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Morgan Stanley on May 22, 2023 offering an Equal-weight rating for the stock and assigned a target price of $8 to it. Coverage by Needham stated Recursion Pharmaceuticals Inc (RXRX) stock as a Buy in their note to investors on March 16, 2023, suggesting a price target of $17 for the stock. On September 16, 2022, KeyBanc Capital Markets Initiated their recommendations, while on April 18, 2022, BofA Securities Downgrade their ratings for the stock with a price target of $10. Stock get a Mkt perform rating from SVB Leerink on March 04, 2022.
